期刊
JOURNAL OF PROTEOME RESEARCH
卷 14, 期 8, 页码 3174-3187出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jproteome.5b00105
关键词
chronic phencyclidine (PCP) rat model; schizophrenia; LC-MSE; SRM; metabonomics; multiplex immunoassay; proteomics
资金
- Stanley Medical Research Institute (SMRI)
- Innovative Medicines Initiative for Novel Methods leading to New Medications in Depression and Schizophrenia (IMI NEWMEDS)
- Dutch Fund for Economic Structure Reinforcement [0908]
- NeuroBasic PharmaPhenomics project
- Waters Corporation
Schizophrenia is a neuropsychiatric disorder affecting 1% of the world's population. Due to both a broad range of symptoms and disease heterogeneity, current therapeutic approaches to treat schizophrenia fail to address all symptomatic manifestations of the disease. Therefore, disease models that reproduce core pathological features of schizophrenia are needed for the elucidation of pathological disease mechanisms. Here, we employ a comprehensive global label-free liquid chromatography mass spectrometry proteomic (LC-MSE) and metabonomic (LC-MS) profiling analysis combined with the targeted proteomics (selected reaction monitoring and multiplex immunoassay) of serum and brain tissues to investigate a chronic phencyclidine (PCP) rat model in which glutamatergic hypofunction is induced through noncompetitive NMDAR-receptor antagonism. Using a multiplex immunoassay, we identified alterations in the levels of several c-ytokines (IL-5, IL-2, and IL-1 beta) and fibroblast growth factor-2. Extensive proteomic and metabonomic brain tissue profiling revealed a more prominent effect of chronic PCP treatment on both the hippocampal proteome and metabonome compared to the effect on the frontal cortex. Bioinformatic pathway analysis confirmed prominent abnormalities in NMDA-receptor-associated pathways in both brain regions, as well as alterations in other neurotransmitter systems such as kainate, AMPA, and GABAergic signaling in the hippocampus and in proteins associated with neurodegeneration. We further identified abundance changes in the level of the superoxide dismutase enzyme (SODC) in both the frontal cortex and hippocampus, which indicates alterations in oxidative stress and substantiates the apoptotic pathway alterations. The present study could lead to an increased understanding of how perturbed glutamate receptor signaling affects other relevant biological pathways in schizophrenia and, therefore, support drug discovery efforts for the improved treatment of patients suffering from this debilitating psychiatric disorder.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据